Consensus HK inno.N Corporation

Equities

A195940

KR7195940002

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
37,700 ^KRW	-1.44%		-0.79%	-15.19%

2022	Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights from HK inno.N Corporation to Develop and Commercialize Tegoprazan in the U.S. and Canada	CI
2022	Sebela Pharmaceuticals Enters an Exclusive Partnership with HK inno.N Corporation	CI

Evolution of the average Target Price on HK inno.N Corporation

Price target over the last 5 years

History of analyst recommendation changes

f5f22294ae77e9571aa749daef3.2rpDhas7d4mD-FISoV1YKU3ACmyKqCFUrbOF9ZITVKQ.6eMx6MleKPnWwCd9wzwJXXuyXzbMwRFnn8LUncJ9AOCw3jG2nGEQxOrOIQ~131b1301aa4ef9985ca34acb2ec5c705

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

37,700 KRW

Average target price

53,750 KRW

Spread / Average Target

+42.57%

High Price Target

61,000 KRW

Spread / Highest target

+61.80%

Low Price Target

48,000 KRW

Spread / Lowest Target

+27.32%

Consensus detail

Consensus revision (last 18 months)

Ratings for HK inno.N Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar